215 related articles for article (PubMed ID: 10027577)
1. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Greig NH; Holloway HW; De Ore KA; Jani D; Wang Y; Zhou J; Garant MJ; Egan JM
Diabetologia; 1999 Jan; 42(1):45-50. PubMed ID: 10027577
[TBL] [Abstract][Full Text] [Related]
2. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
3. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
[TBL] [Abstract][Full Text] [Related]
4. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
Tourrel C; Bailbé D; Meile MJ; Kergoat M; Portha B
Diabetes; 2001 Jul; 50(7):1562-70. PubMed ID: 11423477
[TBL] [Abstract][Full Text] [Related]
6. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
8. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight.
Gedulin BR; Nikoulina SE; Smith PA; Gedulin G; Nielsen LL; Baron AD; Parkes DG; Young AA
Endocrinology; 2005 Apr; 146(4):2069-76. PubMed ID: 15618356
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
10. Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice.
Winzell MS; Ahrén B
J Mol Endocrinol; 2008 Feb; 40(2):93-100. PubMed ID: 18234911
[TBL] [Abstract][Full Text] [Related]
11. Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
Malendowicz LK; Macchi C; Nussdorfer GG; Nowak KW; Zyterska A; Ziolkowska A
Int J Mol Med; 2003 Jun; 11(6):763-6. PubMed ID: 12736719
[TBL] [Abstract][Full Text] [Related]
12. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
[TBL] [Abstract][Full Text] [Related]
13. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.
Egan JM; Meneilly GS; Elahi D
Am J Physiol Endocrinol Metab; 2003 Jun; 284(6):E1072-9. PubMed ID: 12475750
[TBL] [Abstract][Full Text] [Related]
14. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Xu G; Stoffers DA; Habener JF; Bonner-Weir S
Diabetes; 1999 Dec; 48(12):2270-6. PubMed ID: 10580413
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
16. Evidence that glucagon stimulates insulin secretion through its own receptor in rats.
Kawai K; Yokota C; Ohashi S; Watanabe Y; Yamashita K
Diabetologia; 1995 Mar; 38(3):274-6. PubMed ID: 7758872
[TBL] [Abstract][Full Text] [Related]
17. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
18. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
19. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
Sahraoui A; Winzell MS; Gorman T; Smith DM; Skrtic S; Hoeyem M; Abadpour S; Johansson L; Korsgren O; Foss A; Scholz H
PLoS One; 2015; 10(3):e0121204. PubMed ID: 25793295
[TBL] [Abstract][Full Text] [Related]
20. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
